We are proud to share that our latest case report has been published in Frontiers in Oncology!

In this study, we describe a patient with advanced-stage prostate cancer and extensive bone metastases who responded positively to our personalized peptide-based immunization therapy (BITAP). Administered as a monotherapy, BITAP was associated with regression of both metastatic and primary tumor lesions, stabilization of PSA levels, and only mild, short-term side effects.

This case underscores the potential of personalized peptide immunization as a promising therapeutic approach for treatment-resistant prostate cancer.

We are deeply grateful to everyone who helped make this work possible.

Read the full article here.